Emeh Prosper, Englund Maria, Harun Said, Santisteban Valencia Zulma, Revell Jefferson, Hugerth Andreas, Davies Nigel, Bergström Christel A S
The Swedish Drug Delivery Center, Department of Pharmacy, Uppsala University BMC, P.O Box 580, Uppsala 751 23, Sweden; Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg 431 83, Sweden.
Drug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg 431 83, Sweden.
J Control Release. 2025 Aug 19;386:114144. doi: 10.1016/j.jconrel.2025.114144.
Oral delivery of therapeutic peptides is limited by degradation by digestive proteases and poor gastrointestinal permeability. We have investigated how physicochemical properties, including degree of lipidation and degree of amino acid sequence modification, along with formulation with a permeation enhancer (PE), influence the enzymatic stability and intestinal absorption of glucagon-like peptide-1(GLP-1) receptor agonists. We compared four peptides: J211 (non-lipidated; modified), J229 (mono-lipidated; modified), MEDI7219 (bis-lipidated; modified), and semaglutide (mono-lipidated control; least modified). J211, J229 and MEDI7219 have similar amino acid modifications in the peptide sequence to reduce the number of labile proteolytic sites. An in vitro head-to-head comparison between MEDI7219 and semaglutide showed that MEDI7219 was more proteolytically stable (% remaining after 90 min) than semaglutide, which was degraded completely within 10 min. Notably, co-formulation with sodium caprate (C10) improved semaglutide stability, and at least doubled its half-life. Results from in vivo studies in rats following intraduodenal bolus administration, showed that in the absence of C10, the absorption of all the peptides was minimal, with cumulative fractions absorbed below 1 % for all four compounds. Co-formulation with C10 increased the bioavailability of the modified peptides by 35-40-fold, with J211, J229, and MEDI7219 reaching 7.5 %, 4 %, and 17.3 % respectively. Semaglutide's bioavailability improved by ∼200-fold, however bioavailability did not exceed 2 %. These results demonstrate that C10 enhances peptide absorption primarily by increasing intestinal permeability but also likely by improving enzymatic stability of a labile peptide like semaglutide. Furthermore, when comparing the three modified peptides, the degree of lipidation positively correlated with increased intestinal absorption in both the presence and absence of C10.
治疗性肽的口服给药受到消化蛋白酶降解和胃肠道渗透性差的限制。我们研究了包括脂化程度和氨基酸序列修饰程度在内的物理化学性质,以及与渗透促进剂(PE)的配方,如何影响胰高血糖素样肽-1(GLP-1)受体激动剂的酶稳定性和肠道吸收。我们比较了四种肽:J211(非脂化;修饰)、J229(单脂化;修饰)、MEDI7219(双脂化;修饰)和司美格鲁肽(单脂化对照;修饰最少)。J211、J229和MEDI7219在肽序列中具有相似的氨基酸修饰,以减少不稳定蛋白水解位点的数量。MEDI7219和司美格鲁肽之间的体外直接比较表明,MEDI7219比司美格鲁肽具有更高的蛋白水解稳定性(90分钟后剩余百分比),司美格鲁肽在10分钟内完全降解。值得注意的是,与癸酸钠(C10)共同配方提高了司美格鲁肽的稳定性,并使其半衰期至少延长了一倍。十二指肠推注给药后大鼠体内研究的结果表明,在没有C10的情况下,所有肽的吸收都很少,所有四种化合物的累积吸收分数均低于1%。与C10共同配方使修饰肽的生物利用度提高了35至40倍,J211、J229和MEDI7219分别达到7.5%、4%和17.3%。司美格鲁肽的生物利用度提高了约200倍,但生物利用度不超过2%。这些结果表明,C10主要通过增加肠道通透性来增强肽的吸收,但也可能通过提高像司美格鲁肽这样不稳定肽的酶稳定性来实现。此外,在比较三种修饰肽时,无论有无C10,脂化程度与肠道吸收增加呈正相关。